FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381803477> ?p ?o ?g. }

• W4381803477 endingPage "470" @default.
• W4381803477 startingPage "465" @default.
• W4381803477 abstract "Anaplastic lymphoma kinase-positive (ALK-positive) lung adenocarcinoma with multiple liver metastases accounts for a relatively small number of cases of non-small cell lung cancer. Several ALK-tyrosine kinase inhibitors (ALK-TKIs) are available for the treatment of lung cancer. However, there is limited evidence on the treatment of multiple liver metastases in patients with lung cancer that are refractory to ALK-TKIs. We report the case of a 42-year-old male patient with ALK-positive lung adenocarcinoma who experienced rapid progression to multiple liver metastases while receiving treatment with alectinib. Biopsy of the liver metastases revealed echinoderm microtubule-associated protein-like 4-ALK (EML4-ALK) fusion and tumor protein p53 (TP53) mutation; notably, ALK secondary mutations were not detected. Despite the sequential administration of third-generation ALK-TKIs, the liver metastases did not respond, the serum levels of total bilirubin and biliary enzymes continued to increase, and the patient's general appearance worsened. Finally, the patient exhibited a remarkable clinical response to treatment with a combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP). ABCP is one of the optimal options for ALK-positive lung cancer with liver metastasis that is refractory to ALK-TKIs therapy." @default.
• W4381803477 created "2023-06-24" @default.
• W4381803477 creator A5000338747 @default.
• W4381803477 creator A5012788363 @default.
• W4381803477 creator A5013701729 @default.
• W4381803477 creator A5021117068 @default.
• W4381803477 creator A5022308366 @default.
• W4381803477 creator A5026858037 @default.
• W4381803477 creator A5028570171 @default.
• W4381803477 creator A5034162457 @default.
• W4381803477 creator A5047912612 @default.
• W4381803477 creator A5048704135 @default.
• W4381803477 creator A5058702364 @default.
• W4381803477 creator A5065516346 @default.
• W4381803477 creator A5087922163 @default.
• W4381803477 creator A5089485028 @default.
• W4381803477 date "2023-06-01" @default.
• W4381803477 modified "2023-10-06" @default.
• W4381803477 title "Remarkable Clinical Response of ALK-Rearranged/TP53-Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report" @default.
• W4381803477 cites W2012295597 @default.
• W4381803477 cites W2035658420 @default.
• W4381803477 cites W2062783581 @default.
• W4381803477 cites W2156906256 @default.
• W4381803477 cites W2169083371 @default.
• W4381803477 cites W2482427906 @default.
• W4381803477 cites W2561459036 @default.
• W4381803477 cites W2588632379 @default.
• W4381803477 cites W2785110924 @default.
• W4381803477 cites W2791040477 @default.
• W4381803477 cites W2805354595 @default.
• W4381803477 cites W2889170871 @default.
• W4381803477 cites W2936661866 @default.
• W4381803477 cites W2999090889 @default.
• W4381803477 cites W3003499321 @default.
• W4381803477 cites W3015901031 @default.
• W4381803477 cites W3084409519 @default.
• W4381803477 cites W3111588936 @default.
• W4381803477 cites W3128010851 @default.
• W4381803477 cites W3129769609 @default.
• W4381803477 cites W3155376330 @default.
• W4381803477 cites W3171656849 @default.
• W4381803477 cites W3173076954 @default.
• W4381803477 cites W3181431627 @default.
• W4381803477 cites W4252867417 @default.
• W4381803477 doi "https://doi.org/10.2147/ott.s404035" @default.
• W4381803477 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37384219" @default.
• W4381803477 hasPublicationYear "2023" @default.
• W4381803477 type Work @default.
• W4381803477 citedByCount "0" @default.
• W4381803477 crossrefType "journal-article" @default.
• W4381803477 hasAuthorship W4381803477A5000338747 @default.
• W4381803477 hasAuthorship W4381803477A5012788363 @default.
• W4381803477 hasAuthorship W4381803477A5013701729 @default.
• W4381803477 hasAuthorship W4381803477A5021117068 @default.
• W4381803477 hasAuthorship W4381803477A5022308366 @default.
• W4381803477 hasAuthorship W4381803477A5026858037 @default.
• W4381803477 hasAuthorship W4381803477A5028570171 @default.
• W4381803477 hasAuthorship W4381803477A5034162457 @default.
• W4381803477 hasAuthorship W4381803477A5047912612 @default.
• W4381803477 hasAuthorship W4381803477A5048704135 @default.
• W4381803477 hasAuthorship W4381803477A5058702364 @default.
• W4381803477 hasAuthorship W4381803477A5065516346 @default.
• W4381803477 hasAuthorship W4381803477A5087922163 @default.
• W4381803477 hasAuthorship W4381803477A5089485028 @default.
• W4381803477 hasBestOaLocation W43818034771 @default.
• W4381803477 hasConcept C117643217 @default.
• W4381803477 hasConcept C121608353 @default.
• W4381803477 hasConcept C126322002 @default.
• W4381803477 hasConcept C143998085 @default.
• W4381803477 hasConcept C2775949291 @default.
• W4381803477 hasConcept C2776232967 @default.
• W4381803477 hasConcept C2776256026 @default.
• W4381803477 hasConcept C2776694085 @default.
• W4381803477 hasConcept C2777701055 @default.
• W4381803477 hasConcept C2777802072 @default.
• W4381803477 hasConcept C2778239845 @default.
• W4381803477 hasConcept C2779013556 @default.
• W4381803477 hasConcept C2779220645 @default.
• W4381803477 hasConcept C2779422266 @default.
• W4381803477 hasConcept C2780030458 @default.
• W4381803477 hasConcept C2781182431 @default.
• W4381803477 hasConcept C2781451048 @default.
• W4381803477 hasConcept C502942594 @default.
• W4381803477 hasConcept C71924100 @default.
• W4381803477 hasConceptScore W4381803477C117643217 @default.
• W4381803477 hasConceptScore W4381803477C121608353 @default.
• W4381803477 hasConceptScore W4381803477C126322002 @default.
• W4381803477 hasConceptScore W4381803477C143998085 @default.
• W4381803477 hasConceptScore W4381803477C2775949291 @default.
• W4381803477 hasConceptScore W4381803477C2776232967 @default.
• W4381803477 hasConceptScore W4381803477C2776256026 @default.
• W4381803477 hasConceptScore W4381803477C2776694085 @default.
• W4381803477 hasConceptScore W4381803477C2777701055 @default.
• W4381803477 hasConceptScore W4381803477C2777802072 @default.
• W4381803477 hasConceptScore W4381803477C2778239845 @default.
• W4381803477 hasConceptScore W4381803477C2779013556 @default.
• W4381803477 hasConceptScore W4381803477C2779220645 @default.
• W4381803477 hasConceptScore W4381803477C2779422266 @default.

• next